INCMGA00012 + INCAGN02385 + INCAGN02390

This is an investigational **combination therapy** consisting of three distinct monoclonal antibodies: - **INCMGA00012 (retifanlimab)**: an anti–PD-1 monoclonal antibody that blocks the programmed death-1 (PD-1) immune checkpoint, thereby enhancing T-cell–mediated immune responses against tumor cells. - **INCAGN02385**: an anti–LAG-3 monoclonal antibody directed against lymphocyte-activation gene 3 (LAG-3), another immune checkpoint that regulates T-cell exhaustion and immune suppression. - **INCAGN02390**: an anti–TIM-3 monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), an immune checkpoint implicated in limiting effector T-cell function in tumors. The **combination is under investigation for the treatment of advanced malignancies**, including locally advanced or metastatic solid tumors that have failed standard therapies. Studies seek to establish safe and effective dosing regimens and to assess initial efficacy and safety of multi-checkpoint blockade in cancer patients[3][6][9].

Other names

INCAGN02385 + INCAGN02390 + INCMGA00012